Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13833434 | 0.73 | TYMS (0.36) | — | |
| SCHEMBL24339367 | 0.69 | BCAT2 (0.41) | PARP1GDABCAT2ALDH1A1HPGD | |
| SCHEMBL24338103 | 0.69 | POLB (0.43) | PARP1GDABCAT2ALDH1A1HPGD | |
| SCHEMBL18956077 | 0.68 | CA12 (0.43) | PARP1ALDH1A1PIM1GAASRC | |
| SCHEMBL24302773 | 0.68 | RAB9A (0.49) | ALDH1A1GAA | |
| SCHEMBL1787033 | 0.67 | RAB9A (0.51) | PARP1ALDH1A1HPGDPDPK1KDM4E | |
| SCHEMBL22528923 | 0.65 | ADORA1 (0.39) | PARP1ALDH1A1KDM4ESRC | |
| SCHEMBL13833428 | 0.63 | DHFR (0.41) | — | |
| SCHEMBL18964989 | 0.63 | NOTUM (0.42) | PARP1ALDH1A1PIM1GAA | |
| SCHEMBL22528854 | 0.63 | PDPK1 (0.40) | PARP1BCAT2HPGDPDPK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | PARP1 4016/4885GDA 660/4885BCAT2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.